Eukles Asset Management Purchases New Shares in Solventum Co. (NYSE:SOLV)

Eukles Asset Management purchased a new stake in shares of Solventum Co. (NYSE:SOLV) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 629 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently made changes to their positions in SOLV. Partnership Wealth Management LLC bought a new stake in Solventum in the second quarter worth about $26,000. Richard W. Paul & Associates LLC bought a new stake in Solventum in the second quarter worth about $26,000. Family Firm Inc. bought a new stake in Solventum in the second quarter worth about $26,000. M&R Capital Management Inc. bought a new stake in Solventum in the second quarter worth about $27,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in Solventum in the second quarter worth about $27,000.

Analysts Set New Price Targets

Several analysts have commented on SOLV shares. Bank of America lowered their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 25th. Morgan Stanley lowered their price objective on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Wells Fargo & Company lowered their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. The Goldman Sachs Group boosted their price target on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. Finally, Argus assumed coverage on shares of Solventum in a research report on Monday, June 24th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $58.25.

Solventum Price Performance

NYSE SOLV opened at $64.11 on Monday. The company has a 50 day simple moving average of $55.60. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, August 8th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.46 by $0.10. The firm had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.05 billion. The firm’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts expect that Solventum Co. will post 6.38 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.